The test improved prediction of patient benefit from anti-PD-1 immune checkpoint inhibitors (ICIs) as a monotherapy and with ...

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations ... of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) ...

BPT958, a bifunctional PD-1 immunoconjugate with a masked IL-2 payload designed to be processed specifically in the tumor microenvironment ...

Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Researchers from the National Defense Medical Center in Taiwan have identified an increased risk of psoriasis in patients ...

The global burden of digestive tract tumors is profound, with these cancers accounting for nearly half of all malignant ...

Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...

We are carefully prioritizing our resources for the most promising programs. For example, we are advancing Trodelvy in first-line PD-L1 high metastatic non-small cell lung cancer, where we have seen ...

Q3 2024 Earnings Call Transcript November 6, 2024 Coherus BioSciences, Inc. beats earnings expectations. Reported EPS is ...

Persister cells (PCs) and cancer stem cells (CSCs), which exhibit heightened ... Emerging immunotherapies, like PD-1 and PD-L1 inhibitors, have also been linked to ferroptosis induction. PD-L1 ...

Combining the checkpoint inhibitor atezolizumab with targeted therapy led to improvements in overall survival in patients ...